Chardan Capital Reaffirms “Buy” Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

Rocket Pharmaceuticals (NASDAQ:RCKT)‘s stock had its “buy” rating reissued by equities research analysts at Chardan Capital in a report issued on Friday,Benzinga reports. They currently have a $11.00 price objective on the biotechnology company’s stock. Chardan Capital’s target price indicates a potential upside of 191.78% from the stock’s previous close.

RCKT has been the topic of a number of other reports. Wall Street Zen lowered Rocket Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, March 8th. The Goldman Sachs Group increased their price target on Rocket Pharmaceuticals to $3.00 and gave the company a “sell” rating in a report on Monday, March 2nd. Lifesci Capital upgraded Rocket Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, February 26th. TD Cowen upgraded Rocket Pharmaceuticals to a “hold” rating in a report on Friday, December 19th. Finally, Cantor Fitzgerald upped their target price on Rocket Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Friday, February 27th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $13.79.

Rocket Pharmaceuticals Price Performance

Shares of RCKT stock opened at $3.77 on Friday. The firm has a fifty day simple moving average of $4.03 and a 200-day simple moving average of $3.64. The company has a market capitalization of $411.38 million, a PE ratio of -1.88 and a beta of 0.39. Rocket Pharmaceuticals has a twelve month low of $2.19 and a twelve month high of $8.26. The company has a current ratio of 6.38, a quick ratio of 6.38 and a debt-to-equity ratio of 0.07.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.04. During the same quarter in the previous year, the company posted ($0.62) EPS. Equities research analysts anticipate that Rocket Pharmaceuticals will post -2.83 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Gaurav Shah sold 12,279 shares of the firm’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $3.31, for a total value of $40,643.49. Following the transaction, the chief executive officer directly owned 1,052,045 shares in the company, valued at approximately $3,482,268.95. This trade represents a 1.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Martin Wilson sold 12,253 shares of Rocket Pharmaceuticals stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,557.43. Following the completion of the transaction, the general counsel directly owned 683,376 shares of the company’s stock, valued at $2,261,974.56. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 29,415 shares of company stock valued at $97,398. 24.76% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Rocket Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Prudential Financial Inc. bought a new position in Rocket Pharmaceuticals in the second quarter worth about $25,000. Franklin Resources Inc. bought a new position in shares of Rocket Pharmaceuticals during the fourth quarter valued at approximately $38,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Rocket Pharmaceuticals during the 4th quarter worth approximately $42,000. CANADA LIFE ASSURANCE Co raised its position in shares of Rocket Pharmaceuticals by 94.4% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 12,202 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 5,926 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of Rocket Pharmaceuticals in the 3rd quarter worth approximately $40,000. Institutional investors and hedge funds own 98.39% of the company’s stock.

Key Rocket Pharmaceuticals News

Here are the key news stories impacting Rocket Pharmaceuticals this week:

• Positive Sentiment: FDA approval of KRESLADI for severe pediatric LAD‑I — regulatory green light expands Rocket’s commercial path for a first‑in‑class gene therapy for a fatal childhood disorder; approval is narrowly targeted to patients without an HLA‑matched sibling donor, and the decision creates revenue potential and clinical/regulatory validation that could benefit the company’s pipeline. Proactive: Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI
• Positive Sentiment: Industry and media coverage emphasize milestone nature and platform validation — outlets note the approval could “clear the way” for future Rocket products, which supports longer‑term upside if the company executes commercially. BioSpace: Rocket’s Gene Therapy Wins FDA Greenlight
• Positive Sentiment: Analyst reaffirmation with a high price target — Chardan Capital reiterated a Buy and set an $11 target, signaling street conviction and implying substantial upside from current levels if commercialization prospects materialize. Benzinga: Chardan reaffirms Buy, $11 PT
• Neutral Sentiment: Unusually large options activity — a surge in call buying (noted the prior day) indicates speculative/short‑term trader interest around the approval news; this can amplify volatility but doesn’t directly change fundamentals. Seeking Alpha transcript and options note
• Negative Sentiment: Commercial and execution risks remain — small patient population for LAD‑I, reimbursement/pricing negotiations, manufacturing scale‑up, and post‑approval commitments (including potential confirmatory trials) could limit near‑term revenue and increase spending; these uncertainties explain why shares remain volatile and below some long‑term targets until commercial traction is shown. Reuters: Coverage of approval and market reaction

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.